drugset / Trial / NCT04578873
Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults
Phase 1
Completed
75 enrolled
Qpex Biopharma, Inc.
Biomedical Advanced Research and Development Authority · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
This Phase 1 study will assess the safety, tolerability, and pharmacokinetics (PK) of QPX7831, a beta-lactamase inhibitor, when administered orally in single ascending doses and in multiple ascending doses to heathy adult subjects.
Timeline
- Start
- 2021-04-13
- Primary completion
- 2022-08-30
- Completion
- 2022-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QPX7831 | Unknown | — | Oral |